The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
As part of the PMGDisha-CoWIN integration, Mercer | Mettl has aggregated the database of 5 crore Aadhaar-authenticated and registered candidates, which is now being utilized to deliver vaccinations to the last mile populace
The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The funds will be used to buy medicines, enhance oxygen supply and augment the bed capacity in the local and district level hospitals
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
Domestic market and developing countries will need doses of Indian vaccines
Subscribe To Our Newsletter & Stay Updated
